Back

Efficacy of enlicitide across ESC cardiovascular risk categories in two CORALreef phase 3 trials

28 August 2026 (11:05 - 11:15)
Organised by: Logo
Congress Presentation Part of: New insights into lipid-lowering pharmacotherapy Lipid-Lowering Agents ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Professor Erik Stroes

AmsterdamUMC location AMC, Amsterdam (Netherlands (The))

5 More presentations in this session

Presentation thumbnail
Safety, tolerability, pharmacokinetics and pharmacodynamics of HRS-1301, an oral PCSK9 inhibitor, in healthy participants: a first-in-human, randomized, double-blind, placebo-controlled phaseⅠtrial
Professor S. Zhong (Guangzhou, CN)
Abstract Slides
Presentation thumbnail
Lipoprotein(a) variability in high CV risk patients with hypertriglyceridemia and controlled LDL-C on statin therapy – REDUCE-IT Lp(a) Variability
Doctor D. Bhatt (New York City, US)
Abstract Slides
Presentation thumbnail
Evolocumab and risk of a first myocardial infarction: a prespecified analysis of the VESALIUS-CV trial
Doctor G. De Ferrari (Turin, IT)
Abstract Slides
Presentation thumbnail
Intra-coronary imaging before and after PCSK9 inhibition stratified by residual inflammatory risk: a serial imaging sub-study of YELLOW III
Doctor P. C Revaiah (New York, US)
Abstract Slides
Presentation thumbnail
ION775, a long-acting siRNA targeting APOC3: single-dose, 12-month results in participants with moderate hypertriglyceridemia
Professor S. Tsimikas (La Jolla, US)
Abstract Slides

Access the full session

Session thumbnail
New insights into lipid-lowering pharmacotherapy
Video

The Event

Event poster

ESC Congress 2026

28 August 2026 11:05 CET
You may be interested in
thumbnail
Congress Presentation
The COR Lipid-Registry: The effectiveness of the strike early and strike strong strategy (SES) in patients with high cardiovascular risk
20 March 2026
thumbnail
Congress Presentation
Indirect comparison of the safety and efficacy of alirocumab and evolocumab: from a comprehensive meta-analysis of 30 randomized controlled trials
3 September 2019
thumbnail
Congress Presentation
LIBerate-HeFH - a novel PCSK9-inhibitor in heterozygous FH
28 August 2023
thumbnail
Congress Presentation
Evolocumab rapidly reverses impaired coronary endothelial function in six weeks in people living with HIV and in patients with dyslipidemia
2 September 2019

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources